Design and Synthesis of Novel Heterobiaryl Amides As Metabotropic Glutamate Receptor Subtype 5 Antagonists

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2007 Mar 6

PMID 17336520

Citations 9

Authors

Santosh S Kulkarni

Amy Hauck Newman

Affiliations

Soon will be listed here.

Abstract

A series of heterobiaryl amides was designed and synthesized as novel mGluR5 antagonists. The synthesis using palladium catalyzed Suzuki-Miyaura cross-coupling reactions provided an array of compounds with a range of in vitro activities. In particular, compound 9e, 4(3,5-difluorophenyl)-N-(6-methylpyridin-1-yl)picolinamide, exhibited nanomolar affinity at the mGluR5 and will serve as a template for future drug design.

Citing Articles

Metabotropic glutamate receptor 5 negative allosteric modulators as novel tools for in vivo investigation.

Keck T, Zou M, Zhang P, Rutledge R, Newman A ACS Med Chem Lett. 2012; 3(7):544-549.

PMID: 22924094 PMC: 3424002. DOI: 10.1021/ml3000726.

Fragile X syndrome: an update on developing treatment modalities.

Healy A, Rush R, Ocain T ACS Chem Neurosci. 2012; 2(8):402-10.

PMID: 22860169 PMC: 3369755. DOI: 10.1021/cn200019z.

Recent advances in the design and development of novel negative allosteric modulators of mGlu(5).

Emmitte K ACS Chem Neurosci. 2011; 2(8):411-432.

PMID: 21927649 PMC: 3172159. DOI: 10.1021/cn2000266.

Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5.

Zou M, Cao J, Rodriguez A, Conn P, Newman A Bioorg Med Chem Lett. 2011; 21(9):2650-4.

PMID: 21295978 PMC: 3081927. DOI: 10.1016/j.bmcl.2010.12.110.

Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5.

Zhang P, Zou M, Rodriguez A, Conn P, Newman A Bioorg Med Chem. 2010; 18(9):3026-35.

PMID: 20382541 PMC: 2871681. DOI: 10.1016/j.bmc.2010.03.053.

References

Cosford N, Tehrani L, Roppe J, Schweiger E, Smith N, Anderson J . 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem. 2003; 46(2):204-6. DOI: 10.1021/jm025570j. View

Popik P, Wrobel M . Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology. 2003; 43(8):1210-7. DOI: 10.1016/s0028-3908(02)00309-x. View

Swanson C, Bures M, Johnson M, Linden A, Monn J, Schoepp D . Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005; 4(2):131-44. DOI: 10.1038/nrd1630. View

Li X, Need A, Baez M, Witkin J . Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther. 2006; 319(1):254-9. DOI: 10.1124/jpet.106.103143. View

Shi Q, Savage J, Hufeisen S, Rauser L, Grajkowska E, Ernsberger P . L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J Pharmacol Exp Ther. 2003; 305(1):131-42. DOI: 10.1124/jpet.102.047092. View

Yan Q, Rammal M, Tranfaglia M, Bauchwitz R . Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005; 49(7):1053-66. DOI: 10.1016/j.neuropharm.2005.06.004. View

Slassi A, Isaac M, Edwards L, Minidis A, Wensbo D, Mattsson J . Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr Top Med Chem. 2005; 5(9):897-911. DOI: 10.2174/1568026054750236. View

de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D . Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem. 2006; 49(11):3332-44. DOI: 10.1021/jm051252j. View

Dolan S, Kelly J, Monteiro A, Nolan A . Up-regulation of metabotropic glutamate receptor subtypes 3 and 5 in spinal cord in a clinical model of persistent inflammation and hyperalgesia. Pain. 2003; 106(3):501-512. DOI: 10.1016/j.pain.2003.09.017. View

10.

Paterson N, Semenova S, Gasparini F, Markou A . The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl). 2003; 167(3):257-64. DOI: 10.1007/s00213-003-1432-z. View

11.

Conn P, Pin J . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. DOI: 10.1146/annurev.pharmtox.37.1.205. View

12.

Gasparini F, Floersheim P, Flor P, Heinrich M, Inderbitzin W, Ott D . Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco. 2001; 56(1-2):95-9. DOI: 10.1016/s0014-827x(01)01008-4. View

13.

Iso Y, Grajkowska E, Wroblewski J, Davis J, Goeders N, Johnson K . Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J Med Chem. 2006; 49(3):1080-100. DOI: 10.1021/jm050570f. View

14.

Rodriguez A, Nong Y, Sekaran N, Alagille D, Tamagnan G, Conn P . A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol. 2005; 68(6):1793-802. DOI: 10.1124/mol.105.016139. View

15.

Brodkin J, Busse C, Sukoff S, Varney M . Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav. 2002; 73(2):359-66. DOI: 10.1016/s0091-3057(02)00828-6. View

16.

Malherbe P, Kratochwil N, Muhlemann A, Zenner M, Fischer C, Stahl M . Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J Neurochem. 2006; 98(2):601-15. DOI: 10.1111/j.1471-4159.2006.03886.x. View

17.

Barder T, Walker S, Martinelli J, Buchwald S . Catalysts for Suzuki-Miyaura coupling processes: scope and studies of the effect of ligand structure. J Am Chem Soc. 2005; 127(13):4685-96. DOI: 10.1021/ja042491j. View

18.

Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R . Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001; 132(7):1423-30. PMC: 1572682. DOI: 10.1038/sj.bjp.0703923. View

19.

Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R . mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology. 2004; 29(5):921-8. DOI: 10.1038/sj.npp.1300381. View

20.

Kulkarni S, Nightingale B, Dersch C, Rothman R, Newman A . Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006; 16(13):3371-5. DOI: 10.1016/j.bmcl.2006.04.032. View